Results 191 to 200 of about 17,697 (207)

RIPK1 targeting protects against obesity and atherosclerosis

Trends in Endocrinology & Metabolism, 2021
Unhealthy lifestyles and dietary habits often lead to diet-associated inflammatory diseases such as obesity and atherosclerosis. Recent studies have provided novel insight into the role of RIPK1 in inflammation and metabolism. RIPK1 silencing can reduce diet-induced obesity, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis by reducing ...
Yahya, Sohrabi, Holger, Reinecke
openaire   +2 more sources

Repurposing crizotinib to target RIPK1-dependent cell death

International Immunology, 2022
Abstract Receptor-interacting protein kinase 1 (RIPK1) has emerged as a key regulator of cell death and inflammation, which are implicated in the pathogenesis of many inflammatory and degenerative diseases. RIPK1 is therefore a putative therapeutic target in many of these diseases.
Yajie Yu, Min Li, Shufang Fu, Xiaoyan He, Xinqian Hu, Guofeng Zhu, Jia Wang, Xiaoling You, Yan Mou, Zhi Ye, Jun Wei, Yunhong Zha   +11 more
openaire   +2 more sources

Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs

Trends in Pharmacological Sciences, 2020
The scaffolding function of receptor-interacting protein kinase 1 (RIPK1) regulates prosurvival signaling and inflammatory gene expression, while its kinase activity mediates both apoptosis and necroptosis; the latter involving RIPK3 kinase activity.
Martens, Sofie, Hofmans, Sam, Declercq, Wim, Augustyns, Koen, Vandenabeele, Peter   +4 more
openaire   +3 more sources

RIPK1 inhibits ZBP1-driven necroptosis during development

Nature, 2016
Receptor-interacting protein kinase 1 (RIPK1) promotes cell survival-mice lacking RIPK1 die perinatally, exhibiting aberrant caspase-8-dependent apoptosis and mixed lineage kinase-like (MLKL)-dependent necroptosis. However, mice expressing catalytically inactive RIPK1 are viable, and an ill-defined pro-survival function for the RIPK1 scaffold has ...
Kim, Newton, Katherine E, Wickliffe, Allie, Maltzman, Debra L, Dugger, Andreas, Strasser, Victoria C, Pham, Jennie R, Lill, Merone, Roose-Girma, Søren, Warming, Margaret, Solon, Hai, Ngu, Joshua D, Webster, Vishva M, Dixit   +12 more
openaire   +2 more sources

TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

Trends in Immunology, 2023
Resistance mechanisms have curbed the potential of immune checkpoint blockade (ICB) therapies. Understanding mechanisms that contribute to this resistance should reveal new targets for combinatorial therapy. Tank-binding kinase 1 (TBK1) represents such a target.
Michelle A. Kelliher, Katherine A. Fitzgerald   +1 more
openaire   +2 more sources

RIPK1 Promotes Intrinsic and Extrinsic Resistance to Immunotherapy

Cancer Discovery, 2022
Abstract RIPK1 loss enhances immunotherapy by reshaping immune populations and poising tumor cells for killing.
openaire   +2 more sources

A BAF-fling connection to RIPK1

Cell Research, 2022
Jessica M. Gullett, Thirumala-Devi Kanneganti   +1 more
openaire   +2 more sources

RIPK1 and RIPK3 form mosaic necrosomes

Nature Cell Biology, 2022
Weiwei Qi, Junying Yuan
openaire   +2 more sources

PGAM5 promotes RIPK1-PANoptosome activity by phosphorylating and activating RIPK1 to mediate PANoptosis after subarachnoid hemorrhage in rats

Experimental Neurology
Neuronal death plays a crucial role in early brain injury after subarachnoid hemorrhage (SAH). PANoptosis is a programmed form of cell death regulated by the PANoptosome, which possesses key characteristics of pyroptosis, apoptosis and necroptosis. Phosphoglycerate mutase family member 5 (PGAM5) has specific phosphatase activity that phosphorylates or ...
Duan, Jiajia, Yuan, Wen, Jiang, Enyan, Zhang, Xiaojian, Fang, Zhen, Zeng, Jia, Wang, Jikai, Yan, Xiaoxin, Liu, Aihua, Kong, Fangen, Liu, Fei   +10 more
openaire   +2 more sources

A novel RIPK1 inhibitor attenuates GVHD

Blood, 2023
Geoffrey R, Hill, Motoko, Koyama
openaire   +2 more sources